论文部分内容阅读
PKM2作为有氧糖酵解关键酶,与肿瘤发生发展密切相关,在其诊断、预后及治疗方面均有很好的临床应用价值。恶性肿瘤患者血清中PKM2的浓度显著高于非恶性肿瘤患者及正常人,但在不同亚型的泌尿系统肿瘤中PKM2的诊断价值不同;PKM2与传统肿瘤标志物联合时,能显著提高诊断的灵敏度和特异性;PKM2浓度的上升与OS和PFS降低相关;治疗有效时PKM2浓度随之下降。另外,基础研究提示PKM2是重要的治疗靶点。
As a key enzyme of aerobic glycolysis, PKM2 is closely related to tumorigenesis and development, and has good clinical value in diagnosis, prognosis and treatment. The serum PKM2 concentrations in patients with malignant tumors were significantly higher than those in non-malignant tumors and normal subjects, but the diagnostic value of PKM2 in different subtypes of urological tumors was different. PKM2 combined with traditional tumor markers could significantly improve the diagnostic sensitivity And specificity; the increase in PKM2 concentration is associated with a reduction in OS and PFS; the PKM2 concentration decreases with effective treatment. In addition, basic research suggests that PKM2 is an important therapeutic target.